CSIMarket



Abbott Laboratories  (ABT)
Other Ticker:  
 
 

ABT's Capital Expenditures Growth by Quarter and Year

Abbott Laboratories's Capital Expenditures results by quarter and year




ABT Capital Expenditures (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 614.00 679.00 434.00
III Quarter September - 461.00 496.00 401.00
II Quarter June - 413.00 642.00 468.00
I Quarter March 321.00 397.00 360.00 335.00
FY   321.00 1,885.00 2,177.00 1,638.00



ABT Capital Expenditures first quarter 2022 Y/Y Growth Comment
Abbott Laboratories reported decline in Capital Expenditures in the first quarter 2022 by -19.14% to $ 321.00 millions, from the same quarter in 2021.
The contraction in the first quarter 2022 Abbott Laboratories's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures growth of 0.61%.

Looking into first quarter 2022 results within Major Pharmaceutical Preparations industry 39 other companies have achieved higher Capital Expenditures growth. While Abbott Laboratories' s Capital Expenditures fall of -19.14% ranks overall at the positon no. 1073 in the first quarter 2022.




ABT Capital Expenditures ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - -9.57 % 56.45 % -7.07 %
III Quarter September - -7.06 % 23.69 % 13.28 %
II Quarter June - -35.67 % 37.18 % 57.05 %
I Quarter March -19.14 % 10.28 % 7.46 % 21.82 %
FY   - -13.41 % 32.91 % 17.5 %

Financial Statements
Abbott Laboratories's first quarter 2022 Capital Expenditures $ 321.00 millions ABT's Income Statement
Abbott Laboratories's first quarter 2021 Capital Expenditures $ 397.00 millions Quarterly ABT's Income Statement
New: More ABT's historic Capital Expenditures Growth >>


ABT Capital Expenditures (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - 33.19 % 36.9 % 8.23 %
III Quarter September - 11.62 % -22.74 % -14.32 %
II Quarter June - 4.03 % 78.33 % 39.7 %
I Quarter March -47.72 % -41.53 % -17.05 % -28.27 %
FY (Year on Year)   - -13.41 % 32.91 % 17.5 %




Capital Expenditures first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #40
Healthcare Sector #130
Overall #1073

Capital Expenditures Y/Y Growth Statistics
High Average Low
68.12 % 0.61 % -100 %
(Sep. 30, 2011)   (Dec 31 2011)
Capital Expenditures first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #40
Healthcare Sector #130
Overall #1073
Capital Expenditures Y/Y Growth Statistics
High Average Low
68.12 % 0.61 % -100 %
(Sep. 30, 2011)   (Dec 31 2011)

Capital Expenditures by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Abbott Laboratories's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
111.57 % 6.29 % -100 %
(June 30. 2010)   (Dec 31 2011)


ABT's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2022 Abbott Laboratories realized fall in Capital Expenditures from the forth quarter by -47.72% to $ 321.00 millions, from $ 614.00 millions released in the previous quarter.

This is not important problem, as I. Quarter Capital Expenditures always tend to dip in this quarter.

Within Major Pharmaceutical Preparations industry 154 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Abbott Laboratories's Capital Expenditures growth quarter on quarter, overall rank is 2434.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #155
Healthcare Sector #467
Overall #2434
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #155
Healthcare Sector #467
Overall #2434
Capital Expenditures Q/Q Growth Statistics
High Average Low
111.57 % 6.29 % -100 %
(June 30. 2010)   (Dec 31 2011)


ABT's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2022 Abbott Laboratories disclosed fall in Capital Expenditures from the previous quarter by -47.72% to $ 321.00 millions, from $ 614.00 millions released a quarter before.

When you evaluate current shortcoming in the quarter, you suppose to presume, that usually I. Quarter performance emerge weaker in contrast to the preciding period, Adrian Jansson, Healthcare sector researcher based in Goteborg mentioned.

Within Major Pharmaceutical Preparations industry 154 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Abbott Laboratories's Capital Expenditures growth quarter on quarter, overall rank is 2434.


Abbott Laboratories's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative Capital Expenditures 12 Months Ending $ 1,809.00 $ 1,885.00 $ 1,950.00 $ 1,985.00 $ 2,214.00
Y / Y Capital Expenditures Growth (TTM) -18.29 % -13.41 % 0.93 % 8.06 % 33.13 %
Year on Year Capital Expenditures Growth Overall Ranking # 1028 # 668 # 1332 # 1160 # 683
Seqeuential Capital Expenditures Change (TTM) -4.03 % -3.33 % -1.76 % -10.34 % 1.7 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 1033 # 1880 # 1613 # 2532 # 1248




Cumulative Capital Expenditures growth Comment
Abbott Laboratories's cumulative 12 months Capital Expenditures continue to fall, but on the faster rate at -18.29% year on year, at Mar 31 2022 compare to the -13.41% decrease at Dec 31 2021. If the Abbott Laboratories's fiscal year would end at Mar 31 2022, annual Capital Expenditures would be $1,809 millions.

In the Healthcare sector 124 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 668 to 1028.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
736.03 %
17.11 %
-17.16 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 36
Healthcare Sector # 125
Overall # 1028

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
697.91 %
22.41 %
-36.22 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 36
Sector # 122
S&P 500 # 1033
Cumulative Capital Expenditures growth Comment
Abbott Laboratories's cumulative 12 months Capital Expenditures continue to fall, but on the faster rate at -18.29% year on year, at Mar 31 2022 compare to the -13.41% decrease at Dec 31 2021. If the Abbott Laboratories's fiscal year would end at Mar 31 2022, annual Capital Expenditures would be $1,809 millions.

In the Healthcare sector 124 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 668 to 1028.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
736.03 %
17.11 %
-17.16 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 36
Healthcare Sector # 125
Overall # 1028

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
697.91 %
22.41 %
-36.22 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 36
Sector # 122
S&P 500 # 1033




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
ABT's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for ABT's Competitors
Capital Expenditures Growth for Abbott Laboratories's Suppliers
Capital Expenditures Growth for ABT's Customers

You may also want to know
ABT's Annual Growth Rates ABT's Profitability Ratios ABT's Asset Turnover Ratio ABT's Dividend Growth
ABT's Roe ABT's Valuation Ratios ABT's Financial Strength Ratios ABT's Dividend Payout Ratio
ABT's Roa ABT's Inventory Turnover Ratio ABT's Growth Rates ABT's Dividend Comparisons



Companies with similar Capital Expenditures fall for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Mar 31 2022
Novan Inc.-0.64%$ -0.642 millions
Brookdale Senior Living Inc -1.00%$ -1.003 millions
Alkermes Plc -2.44%$ -2.442 millions
Novabay Pharmaceuticals Inc -4.00%$ -4.000 millions
Shattuck Labs Inc -5.69%$ -5.686 millions
Morphic Holding inc -5.88%$ -5.882 millions
Fulcrum Therapeutics Inc -6.11%$ -6.107 millions
Vbi Vaccines Inc-7.37%$ -7.374 millions
Community Health Systems Inc -7.62%$ -7.619 millions
Sqz Biotechnologies Company-7.69%$ -7.692 millions
Tarsus Pharmaceuticals Inc -8.00%$ -8.000 millions
Inspire Medical Systems inc -8.02%$ -8.024 millions
Becton Dickinson And Company-10.28%$ -10.277 millions
Vertex Pharmaceuticals Inc-10.33%$ -10.329 millions
Xtant Medical Holdings Inc -10.70%$ -10.701 millions
Myriad Genetics Inc -11.27%$ -11.268 millions
Exact Sciences Corporation-11.33%$ -11.332 millions
Inogen Inc -11.41%$ -11.414 millions
Alphatec Holdings Inc -11.81%$ -11.808 millions
Avanos Medical Inc -12.28%$ -12.281 millions
Merck and Co Inc -13.23%$ -13.228 millions
Genocea Biosciences Inc -13.35%$ -13.345 millions
Abbvie Inc -13.83%$ -13.830 millions
Acadia Healthcare Company Inc -13.90%$ -13.897 millions
Procyon Corp-14.32%$ -14.319 millions
Ocugen Inc -14.56%$ -14.559 millions
Davita Inc -15.05%$ -15.047 millions
Biolife Solutions Inc-15.35%$ -15.349 millions
Covetrus Inc -15.38%$ -15.385 millions
Bausch Health Companies Inc -16.18%$ -16.176 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

MLAI's Profile

Stock Price

MLAI's Financials

Business Description

Fundamentals

Charts & Quotes

MLAI's News

Suppliers

MLAI's Competitors

Customers & Markets

Economic Indicators

MLAI's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071